<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038449</url>
  </required_header>
  <id_info>
    <org_study_id>KPC/QSXJ/01</org_study_id>
    <nct_id>NCT05038449</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19</brief_title>
  <official_title>An IIT, Randomized, Single-Center, Open-Lable, Standard Therapy Controlled Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kunming Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed for single-center, randomized, open label, standard therapy&#xD;
      controlled. 60 COVID-19 subjects with a treatment period of 10 days and follow-up until 28&#xD;
      days after enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 6, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery rate of clinical symptoms (fever, cough, expectoration, chest tightness, shortness of breath, dyspnea) and virus negative conversion rate (RT-PCR) at day 7</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the patients' clinical status through the WHO Clinical Progression Scale (scores 0-10) at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>The scale provides a measure of illness severity across a range from 0 (not infected) to 10 (dead)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the patients' clinical status through the WHO Clinical Progression Scale (scores 0-10) at day 10</measure>
    <time_frame>Day 10</time_frame>
    <description>The scale provides a measure of illness severity across a range from 0 (not infected) to 10 (dead)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator usage rate, usage time at day 7</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator usage rate, usage time at day 10</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery rate and virus negative conversion rate (RT-PCR) of 10-day clinical symptoms (fever, cough, sputum expectoration, chest tightness, shortness of breath, dyspnea)</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for the virus negative conversion (RT-PCR)</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for observation in hospital</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in the intensive care unit</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 7: C-reactive protein</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 10: C-reactive protein</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 7: TNF-alfa</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 10: TNF-alfa</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 7: IL-6</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 10: IL-6</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 7: IL-1β</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers at day 10: IL-1β</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in severity markers at day 7: D-dimer</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in severity markers at day 10: D-dimer</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in myocardial damage at day 7: hs-cTn</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in myocardial damage at day 10: hs-cTn</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in myocardial damage at day 7: NT-proBNP</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in myocardial damage at day 10: NT-proBNP</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <condition>Colchicine</condition>
  <arm_group>
    <arm_group_label>Colchicine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The colchicine treatment includes an initial dose of 1 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 6 days and 0.5 mg every 24 hours until the completion of 10 days of total treatment.&#xD;
+ standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine Tablets</intervention_name>
    <description>Colchicine Tablets (Each tablet contains colchicine 0.5mg)</description>
    <arm_group_label>Colchicine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)</description>
    <arm_group_label>Colchicine group</arm_group_label>
    <arm_group_label>Standard therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At the time of signing ICF, the subjects were 18 to 65 years old (including 18 and 65&#xD;
             years old), both men and women;&#xD;
&#xD;
          2. Within 72 hours before screening, any samples confirmed by the laboratory were&#xD;
             positive for SARS-CoV-2;&#xD;
&#xD;
          3. Clinical classification was ordinary type according to the Novel Coronavirus Pneumonia&#xD;
             Diagnosis and Treatment Plan (Trial 8th Edition)；&#xD;
&#xD;
          4. Symptoms appeared ≤ 5 days before randomization; Such as fever, cough, shortness of&#xD;
             breath, sore throat and diarrhea;&#xD;
&#xD;
          5. Subjects were able to communicate well with the investigator, and understand and&#xD;
             comply with the requirements of this study, understand and sign the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe type patients who comply with any of the following：&#xD;
&#xD;
               -  Shortness of breath, RR ≥ 30 times/min;&#xD;
&#xD;
               -  In the resting state, the oxygen saturation is less than or equal to 93%;&#xD;
&#xD;
               -  Arterial oxygen partial pressure (PaO2)/oxygen inhalation concentration (FiO2) ≤&#xD;
                  300 mmHg (1mmHg=0.133kPa). Note: At high altitudes (above 1000 m), PaO2/FiO2&#xD;
                  shall be corrected according to the following formula: PaO2/FiO2 ×&#xD;
                  [760/atmospheric pressure (mmHg)];&#xD;
&#xD;
               -  Pulmonary imaging shows that patients with obvious lesion progression &gt; 50%&#xD;
                  within 24-48 hours.&#xD;
&#xD;
          2. Critical type patients who comply with any of the following：&#xD;
&#xD;
               -  Respiratory failure occurs and mechanical ventilation is required;&#xD;
&#xD;
               -  Shock;&#xD;
&#xD;
               -  ICU monitoring and treatment are required for other organ failure.&#xD;
&#xD;
          3. People who are known to be allergic to the test drug and its components;&#xD;
&#xD;
          4. People with inflammatory bowel disease, chronic diarrhea, malabsorption;&#xD;
&#xD;
          5. People with previous neuromuscular disease;&#xD;
&#xD;
          6. People with severe renal insufficiency (glomerular filtration rate &lt;30 mL/min/1.73m2);&#xD;
&#xD;
          7. People with medical history of liver cirrhosis, active chronic hepatitis, or severe&#xD;
             liver disease with serum GOT or GPT 3 times higher than the normal upper limit;&#xD;
&#xD;
          8. Patients who are taking colchicine or have a history of colchicine treatment (mainly&#xD;
             chronic prescriptions for familial Mediterranean fever or gout);&#xD;
&#xD;
          9. People who have used immunosuppressants, corticosteroids, interleukin-1 inhibitors, or&#xD;
             interleukin-6 inhibitors within 30 days before screening;&#xD;
&#xD;
         10. People who test positive for anti-SARS-CoV-2 immunoglobulin G (IgG);&#xD;
&#xD;
         11. People who have been vaccinated against COVID-19;&#xD;
&#xD;
         12. Any comorbidities that require surgery within 7 days before screening, or&#xD;
             life-threatening comorbidities within 30 days before screening;&#xD;
&#xD;
         13. Suffering from malignant tumor diseases (excluding malignant tumors that have been&#xD;
             cured and have not recurred in the past 5 years, completely resected basal cell and&#xD;
             squamous cell skin cancers, and any type of cancer in situ that has been completely&#xD;
             resected);&#xD;
&#xD;
         14. Suffering from any serious concomitant systemic disease, condition or disorder that&#xD;
             the researcher believes should be prevented from participating in this study;&#xD;
&#xD;
         15. Pregnant or lactating women who have a positive human chorionic gonadotropin (hCG)&#xD;
             test;&#xD;
&#xD;
         16. People who have a fertility plan or do not consent to effective non-drug contraception&#xD;
             during the signing of the ICF to 6 months after the end of the trial;&#xD;
&#xD;
         17. Participated in other clinical studies within 30 days before screening;&#xD;
&#xD;
         18. People who have other factors that the researcher believes are not suitable for&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongzhou Lu, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Public Health Clinical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongzhou Lu, Ph.D</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongzhou Lu, PI</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 5, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Co-Director of Shanghai Public Health Clinical Center affiliated to Fudan University</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Colchicine Tablets</keyword>
  <keyword>IIT Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

